<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tremelimumab &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tremelimumab/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Oct 2026 12:45:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>tremelimumab &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Drug Combinations Compared for Kidney Cancer Recurrence Risk After Surgery</title>
		<link>https://bioengineer.org/drug-combinations-compared-for-kidney-cancer-recurrence-risk-after-surgery/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 23 Oct 2026 12:45:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[adjuvant therapy]]></category>
		<category><![CDATA[adverse events]]></category>
		<category><![CDATA[belzutifan]]></category>
		<category><![CDATA[disease-free survival]]></category>
		<category><![CDATA[durvalumab]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[nephrectomy]]></category>
		<category><![CDATA[Network Meta-Analysis]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[pembrolizumab)]]></category>
		<category><![CDATA[Renal cell carcinoma]]></category>
		<category><![CDATA[tremelimumab]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=449550</guid>

					<description><![CDATA[A network meta-analysis of six randomized trials in 5,838 patients finds that pembrolizumab plus belzutifan offers the strongest protection against recurrence after nephrectomy for high-risk renal cell carcinoma, but the doublet regimens carry a three- to five-fold higher risk of severe side effects.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">449550</post-id>	</item>
	</channel>
</rss>
